Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $46.09 Consensus Price Target from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been assigned an average rating of “Moderate Buy” from the ten research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $46.0909.

Several analysts have recently commented on the stock. B. Riley Financial raised their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 10th.

Insider Activity

In related news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $247,758.99. The trade was a 75.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the transaction, the director owned 7,529 shares in the company, valued at approximately $240,928. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 147,529 shares of company stock valued at $4,509,940. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new position in Capricor Therapeutics during the third quarter worth $1,555,000. HBK Sorce Advisory LLC grew its holdings in shares of Capricor Therapeutics by 33.7% during the third quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock valued at $1,141,000 after buying an additional 42,951 shares during the last quarter. Pier Capital LLC increased its position in shares of Capricor Therapeutics by 35.0% during the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after acquiring an additional 128,837 shares in the last quarter. AlphaQuest LLC increased its position in shares of Capricor Therapeutics by 396.2% during the third quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 23,974 shares in the last quarter. Finally, Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $34.70 on Wednesday. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -15.35 and a beta of 0.48. The business’s 50-day moving average is $29.34 and its 200-day moving average is $20.86. Capricor Therapeutics has a 1 year low of $4.30 and a 1 year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.